This program may contribute to the resistance against traditional anti-TGF-β therapies in fibrotic kidney disease and highlights the PKM2–TEAD2 circuit as a therapeutic target distinct from EMT signaling. This evidence concerns the gene TGFB1 and kidney disorder.